PT-141 vs Melanotan II

Two melanocortin peptides from the same research line — one became a medicine, one did not. Why?

No head-to-head trial — cross-trial comparison
In one paragraphThey are close chemical relatives. Melanotan II activates melanocortin receptors broadly, which is why it tans skin, triggers erections, causes nausea and darkens moles all at once. PT-141 (bremelanotide) is the metabolite that was developed selectively for sexual desire, taken through two phase 3 trials in 1,267 women, and approved in the United States in 2019. Melanotan II never completed later-stage trials and is not approved anywhere.

Side by side

A PT-141C Melanotan II
LYO overall gradeAC
ApprovedYes — US, 2019 (Vyleesi)No, nowhere
Trial base2 phase 3 RCTs, n=1,267Small early-phase studies, n≈3–20
Main studied effectSexual desire in premenopausal women with HSDDSkin tanning; erections in men
Effect sizeStatistically significant, clinically modestTip rigidity 38.0 min vs 3.0 on placebo (n=10)
Receptor selectivityDeveloped for the sexual-desire pathwayBroad — MC1R (pigment) and MC4R (arousal, appetite) together
Documented adverse effectsNausea ~40%, flushing, headache; 18% stoppedNausea, flushing, spontaneous erections, mole darkening; case reports of renal infarction
Melanoma considerationNot a pigment drugDarkens and changes moles, which can mask melanoma
Verdict

PT-141 is what happens when a melanocortin peptide is developed properly: a modest, measured, approved effect with a documented 40% nausea rate. Melanotan II is the same pharmacology without the development — real effects, unquantified risks, no oversight.

The same starting point

Both descend from research on α-melanocyte-stimulating hormone in the 1980s and 1990s. Melanotan II was built as a tanning agent — a tan without ultraviolet — and the erection effect was discovered along the way, memorably, in early volunteer studies. PT-141 is a metabolite of it, and the developers pursued the sexual effect and left the pigment effect behind.

That divergence is the whole story. One went into a regulated development programme; the other went onto the internet.

What development bought

PT-141 went through the RECONNECT programme: two identical phase 3 randomised, placebo-controlled trials in 1,267 premenopausal women with hypoactive sexual desire disorder. Women taking bremelanotide had statistically significant increases in sexual desire and statistically significant reductions in distress related to low desire, across both studies. The effect is real and it is small — a change of about 0.3 to 0.4 on the desire scale.

The same programme quantified the cost: nausea, flushing and headache each affected 10% or more of participants, nausea around 40%, and 18% stopped because of side effects. That is the number you cannot get from an unapproved compound, and it is what makes an informed decision possible.

What skipping development costs

Melanotan II's human evidence is a 10-man crossover for erections and a three-person pilot for tanning. Both showed real effects — mean duration of tip rigidity above 80% was 38.0 minutes against 3.0 on placebo, and the tanning study demonstrated measurable pigmentation from five low doses. Neither tells you the rate of anything at scale.

Because it is non-selective, the wanted and unwanted effects arrive together: pigment, arousal, nausea, appetite suppression. Dermatologists' specific concern is that it darkens and changes existing moles, which complicates the visual detection of melanoma, and case reports describe serious events including kidney infarction. None of that is quantified, because nobody is counting.

Questions people actually ask

Is PT-141 just a cleaner Melanotan II?
Effectively yes — it is a metabolite developed for one of the parent compound's effects, without the pigment activity, and taken through proper trials.
Does Melanotan II work for tanning?
Small studies show it does darken skin. That was never the open question. The open questions are the rate of harm and what accelerating mole pigmentation does to melanoma detection, and those have no answers.
Is PT-141 approved for men?
No. It is approved in the US for premenopausal women with hypoactive sexual desire disorder. Use in men rests on earlier, smaller phase 2 work.

References

  1. 1
  2. 2
  3. 3